全文获取类型
收费全文 | 68659篇 |
免费 | 3770篇 |
国内免费 | 561篇 |
专业分类
耳鼻咽喉 | 264篇 |
儿科学 | 2038篇 |
妇产科学 | 908篇 |
基础医学 | 6278篇 |
口腔科学 | 589篇 |
临床医学 | 5810篇 |
内科学 | 16469篇 |
皮肤病学 | 678篇 |
神经病学 | 1898篇 |
特种医学 | 2112篇 |
外科学 | 7880篇 |
综合类 | 13027篇 |
一般理论 | 9篇 |
预防医学 | 8560篇 |
眼科学 | 306篇 |
药学 | 3745篇 |
49篇 | |
中国医学 | 1522篇 |
肿瘤学 | 848篇 |
出版年
2023年 | 812篇 |
2022年 | 1486篇 |
2021年 | 2106篇 |
2020年 | 1853篇 |
2019年 | 4033篇 |
2018年 | 3714篇 |
2017年 | 2251篇 |
2016年 | 1468篇 |
2015年 | 1629篇 |
2014年 | 4245篇 |
2013年 | 3704篇 |
2012年 | 3639篇 |
2011年 | 4114篇 |
2010年 | 3377篇 |
2009年 | 3102篇 |
2008年 | 3046篇 |
2007年 | 2615篇 |
2006年 | 2541篇 |
2005年 | 1981篇 |
2004年 | 1493篇 |
2003年 | 1251篇 |
2002年 | 917篇 |
2001年 | 852篇 |
2000年 | 780篇 |
1999年 | 616篇 |
1998年 | 468篇 |
1997年 | 477篇 |
1996年 | 361篇 |
1995年 | 385篇 |
1994年 | 314篇 |
1993年 | 222篇 |
1992年 | 216篇 |
1991年 | 184篇 |
1990年 | 139篇 |
1989年 | 141篇 |
1988年 | 147篇 |
1987年 | 120篇 |
1985年 | 971篇 |
1984年 | 1509篇 |
1983年 | 1209篇 |
1982年 | 1211篇 |
1981年 | 1214篇 |
1980年 | 1085篇 |
1979年 | 942篇 |
1978年 | 751篇 |
1977年 | 553篇 |
1976年 | 715篇 |
1975年 | 647篇 |
1974年 | 542篇 |
1973年 | 511篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
71.
72.
73.
74.
75.
76.
77.
78.
79.
80.
《Vaccine》2019,37(43):6310-6316
BackgroundSerotype 3 pneumococcal disease has not substantially declined at the population level after the routine introduction of 13-valent pneumococcal conjugate vaccine (PCV13) into pediatric immunization programs across the globe. This epidemiological finding has generated debate regarding the effectiveness of PCV13 against serotype 3 disease. Evaluating PCV13 effectiveness against serotype 3 is especially critical in adults, where serotype 3 makes up an important amount of remaining pneumococcal disease.MethodsWe performed a systematic review of the published literature to assess the direct effectiveness of PCV13 against serotype 3 community-acquired pneumonia (CAP) among adults. We then estimated overall vaccine effectiveness (VE) using a pooled analysis of the individual-level, raw data.ResultsTwo published studies met inclusion criteria. One was a randomized controlled trial conducted in the Netherlands and published in 2014. The other was a recently-published case-control study conducted in Louisville, Kentucky that used a test-negative design (TND). We also identified a third TND study conducted in Argentina that was recently presented as a conference abstract but is not yet published. All three studies were conducted in adults aged ≥65 years. PCV13 VE against serotype 3 hospitalized CAP was 52.5% (95%CI: 6.2–75.9%) from the pooled analysis of individual-level data from all three studies. Results were similar if the unpublished estimate was excluded (serotype 3 VE = 53.6% [95%CI: 6.7–76.9%]). No heterogeneity was observed.ConclusionsCurrently-available evidence, although limited to three studies, suggests that PCV13 provides direct protection against serotype 3 hospitalized CAP in adults aged ≥65 years. 相似文献